A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine

Summary

A randomized, double-blind and placebo-controlled phase I study to evaluate the safety and immunogenicity of a 9-valent Human Papillomavirus (HPV) vaccine, administered intramuscularly according to a 0, 2, 6-month schedule in 9 to 45 years old healthy Chinese females.

Timeline

Start

2019-03-09

Primary completion

2020-04-30

Completion

2020-04-30

Drugs

Indications